US 12,011,480 B2
Nanoparticle compositions for sustained therapy
Pedro Santamaria, Calgary (CA)
Assigned to UTI LIMITED PARTNERSHIP, Calgary (CA)
Appl. No. 15/572,137
Filed by UTI LIMITED PARTNERSHIP, Calgary (CA)
PCT Filed May 6, 2016, PCT No. PCT/IB2016/000691
§ 371(c)(1), (2) Date Nov. 6, 2017,
PCT Pub. No. WO2016/198932, PCT Pub. Date Dec. 15, 2016.
Claims priority of provisional application 62/157,933, filed on May 6, 2015.
Claims priority of provisional application 62/273,953, filed on Dec. 31, 2015.
Claims priority of provisional application 62/296,032, filed on Feb. 16, 2016.
Prior Publication US 2019/0060484 A1, Feb. 28, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/385 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 47/69 (2017.01); C12N 5/0783 (2010.01)
CPC A61K 39/385 (2013.01) [A61K 39/0008 (2013.01); A61K 47/545 (2017.08); A61K 47/60 (2017.08); A61K 47/6909 (2017.08); A61K 47/6929 (2017.08); A61K 47/6935 (2017.08); A61K 2039/57 (2013.01); A61K 2039/60 (2013.01); A61K 2039/627 (2013.01)] 8 Claims
 
1. A peptide/MHC/nanoparticle complex comprising:
a nanoparticle core,
wherein the nanoparticle core comprises an iron oxide and has a diameter which is from about 1 nm to about 50 nm;
a polyethylene glycol (PEG) linker
that is less than about 5 kilodaltons in molecular weight, and
wherein a non-maleimide functionalized end of the PEG linker is coupled to the nanoparticle core, and the non-maleimide functionalized end comprises an alkoxy, an alkyl, alkyl-amide-alkyl, alkyl-ester-alkyl, alkyl-amide, alkyl-acid, or alkyl-ester; and
a plurality of-PDC-E2122-135/HLA-DRB4*0101/DRA antigen-MHC class II (pMHCII) complexes;
wherein the pMHCII complexes are covalently coupled to the nanoparticle core via the formation of a carbon-sulfur bond between the thiol (—SH) group of a cysteine residue added to the carboxyl terminus of the pMHCs and the maleimide functionalized end of the PEG linker, and
wherein the density of the pMHCII complexes per nanoparticle surface area is from about 0.05 pMHC/100 nm2 to about 25 pMHC/100 nm2.